Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Yeh RW, et al. Among authors: gershlick ah. JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775. JAMA. 2016. PMID: 27022822 Free PMC article. Clinical Trial.
Antiplatelet therapy.
Gershlick AH. Gershlick AH. Hosp Med. 2000 Jan;61(1):15-23. doi: 10.12968/hosp.2000.61.1.1267. Hosp Med. 2000. PMID: 10735148 Review.
Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial.
Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Brinker JA, Raizner AE, Urban P, Heldman AW. Gershlick A, et al. Circulation. 2004 Feb 3;109(4):487-93. doi: 10.1161/01.CIR.0000109694.58299.A0. Epub 2004 Jan 26. Circulation. 2004. PMID: 14744971 Clinical Trial.
Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.
Camenzind E, Wijns W, Mauri L, Boersma E, Parikh K, Kurowski V, Gao R, Bode C, Greenwood JP, Gershlick A, O'Neill W, Serruys PW, Jorissen B, Steg PG; PROTECT Steering Committee and Investigators. Camenzind E, et al. Am Heart J. 2009 Dec;158(6):902-909.e5. doi: 10.1016/j.ahj.2009.10.002. Am Heart J. 2009. PMID: 19958855 Clinical Trial.
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.
Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. Verheugt FW, et al. Among authors: gershlick ah. JACC Cardiovasc Interv. 2011 Feb;4(2):191-7. doi: 10.1016/j.jcin.2010.10.011. JACC Cardiovasc Interv. 2011. PMID: 21349458 Free article.
257 results